Cerebrospinal fluid high mobility group box 1 is associated with neuronal death in subarachnoid hemorrhage

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 2, 2017, Pages 435-443

  Wang, Kuo Chuan ^a   Tang, Sung Chun ^a   Lee, Jing Er ^b   Li, Yu I ^c   Huang, Yi Shuian ^d   Yang, Wei Shiung ^a,c   Jeng, Jiann Shing ^a   Arumugam, Thiruma V ^e   Tu, Yong Kwang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cell death mechanisms; cerebrospinal fluid; inflammation; receptors; subarachnoid hemorrhage

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; ADVANCED GLYCATION END PRODUCT; RECOMBINANT PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CELL VIABILITY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CONVENTIONAL ANGIOGRAPHY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROIMAGING; NEUROLOGICAL INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; RAT; SUBARACHNOID HEMORRHAGE; THERAPY EFFECT; TUNEL ASSAY; ANIMAL; BRAIN; CELL CULTURE; CELL DEATH; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; PROGNOSIS; WISTAR RAT;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; ANIMALS; BRAIN; CELL DEATH; CELLS, CULTURED; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; NEURONS; PROGNOSIS; RATS, WISTAR; RECOMBINANT PROTEINS; SUBARACHNOID HEMORRHAGE;

EID: 85009865420     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16629484     Document Type: Article

References (37)

1. Brisman JL, Song JK and Newell DW. Cerebral aneur-ysms. N Engl J Med 2006; 355: 928-939.
2. Rosengart AJ, Schultheiss KE, Tolentino J, et al. Prognostic factors for outcome in patients with aneurys-mal subarachnoid hemorrhage. Stroke 2007; 38: 2315-2321.
3. Niskanen MM, Hernesniemi JA, Vapalahti MP, et al. One-year outcome in early aneurysm surgery: prediction of outcome. Acta Neurochir (Wien) 1993; 123: 25-32.
4. Everse J and Hsia N. The toxicities of native and modified hemoglobins. Free Radic Biol Med 1997; 22: 1075-1099.
5. Ryter SW and Tyrrell RM. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxy-genase has both pro- and antioxidant properties. Free Radic Biol Med 2000; 28: 289-309.
6. Murakami K, Koide M, Dumont TM, et al. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res 2011; 2: 72-79.
7. Wang KC, Tang SC, Lee JE, et al. Intrathecal lactate predicting hydrocephalus after aneurysmal subarachnoid hemorrhage. J Surg Res 2015; 199: 523-528.
8. Wang KC, Tang SC, Lee JE, et al. Prognostic value of intrathecal heme oxygenase-1 concentration in patients with fisher grade iii aneurysmal subarachnoid hemorrhage. J Neurosurg 2014; 121: 1388-1393.
9. Chen S, Feng H, Sherchan P, et al. Controversies and evolving new mechanisms in subarachnoid hemorrhage. Prog Neurobiol 2014; 115: 64-91.
10. Kamp MA, Dibue M, Etminan N, et al. Evidence for direct impairment of neuronal function by subarachnoid metabolites following sah. Acta Neurochir (Wien) 2013; 155: 255-260.
11. Suzuki H, Kanamaru K, Tsunoda H, et al. Heme oxyge-nase-1 gene induction as an intrinsic regulation against delayed cerebral vasospasm in rats. J Clin Invest 1999; 104: 59-66.
12. Lotze MT and Tracey KJ. High-mobility group box 1 protein (hmgb1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
13. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor rage mediates ischemic brain damage. J Neurosci 2008; 28: 12023-12031.
14. Tang SC, Wang YC, Li YI, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013; 33: 585-594.
15. Faraco G, Fossati S, Bianchi ME, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007; 103: 590-603.
16. Zhang J, Takahashi HK, Liu K, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 2011; 42: 1420-1428.
17. Nakahara T, Tsuruta R, Kaneko T, et al. High-mobility group box 1 protein in csf of patients with subarachnoid hemorrhage. Neurocrit Care 2009; 11: 362-368.
18. Seule M, Muroi C, Sikorski C, et al. Monitoring of cerebral hemodynamics and oxygenation to detect delayed ischemic neurological deficit after aneurysmal subarach-noid hemorrhage. Acta Neurochir Suppl 2013; 115: 57-61.
19. Jennett B and Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1: 480-484.
20. Tang SC, Yeh SJ, Li YI, et al. Evidence for a detrimental role of tlr8 in ischemic stroke. Exp Neurol 2013; 250: 341-347.
21. Tang SC, Arumugam TV, Cutler RG, et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem 2007; 101: 729-736.
22. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007; 104: 13798-13803.
23. Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 2014; 10: 44-58.
24. Sabri M, Lass E and Macdonald RL. Early brain injury: a common mechanism in subarachnoid hemorrhage and global cerebral ischemia. Stroke Res Treat 2013; 2013: 394036.
25. Kumar A, Brown R, Dhar R, et al. Early vs. delayed cerebral infarction after aneurysm repair after subarach-noid hemorrhage. Neurosurgery 2013; 73: 617-623. discussion 623.
26. Fujii M, Yan J, Rolland WB, et al. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res 2013; 4: 432-446.
27. Huang L, Wan J, Chen Y, et al. Inhibitory effects of p38 inhibitor against mitochondrial dysfunction in the early brain injury after subarachnoid hemorrhage in mice. Brain Res 2013; 1517: 133-140.
28. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Immunological response in early brain injury after sah. Acta Neurochir Suppl 2011; 110: 57-61.
29. Kusaka G, Ishikawa M, Nanda A, et al. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2004; 24: 916-925.
30. Musumeci D, Roviello GN and Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in hmgb1-related pathologies. Pharmacol Ther 2014; 141: 347-357.
31. Fang P, Schachner M and Shen YQ. HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 2012; 45: 499-506.
32. de Souza AW, Westra J, Limburg PC, et al. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11: 909-917.
33. Tang SC, Yeh SJ, Tsai LK, et al. Association between plasma levels of hyaluronic acid and functional outcome in acute stroke patients. J Neuroinflamm 2014; 11: 101.
34. Wang H, Wang K, Wang C, et al. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 2013; 20: 113-118.
35. Wang KC, Tsai CP, Lee CL, et al. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 2012; 226: 510-516.
36. Uzawa A, Mori M, Masuda S, et al. Csf high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiat 2013; 84: 517-522.
37. Cid C, Alvarez-Cermeno JC, Regidor I, et al. Caspase inhibitors protect against neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients. J Neuroimmunol 2003; 136: 119-124.